Mankind Pharma has announced it will buy biotech company BSV for a whopping Rs 13,630 crore. The deal brings together a master of mass market products and an intrinsic innovator in the high entry barrier spaces of the healthcare market. It’s an expensive buy and Mankind has gone for broke, raising equity and debt and stalling other planned purchases. Why is the deal so important and how will it transform Mankind Pharma’s position in the industry?
Host Anirban Chowdhury, ET’s pharma expert Vikas Dandekar, Sheetal Sapale from Pharmarack, and Mankind co-founder Rajeev Juneja weigh in.
Check out other interesting episodes from the host like: Risk or Respite: RBI Sets Rules On Fraud, The Blue Screen of Death , Bumpy Rides For EVs in India, Lethal Liquor Part 1: How Moonshine Devastated a Village, India Scorching Part 1, and more!
You can follow Anirban Chowdhury on his social media: Twitter and Linkedin
Catch the latest episode of ‘The Morning Brief’ on ET Play, The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Google Podcasts.
Credits: NDTV Profit, CNBC-TV18
See omnystudio.com/listener for privacy information.